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Abstract
BACKGROUND: Aim of the study was to evaluate accuracy of different dosimetry protocols in estimating the required 131I 
activity to treat hyperthyroid patients. 
MATERIALS AND METHODS: Forty consecutive patients were analysed: twenty-eight Graves’ disease; twelve autonomous 
thyroid nodule (ATN). Maximum-uptake, effective half-time and residence-time were estimated from Radioiodine Uptake Test. 
Residence-time was estimated using a bi-compartmental model. For 131I activity calculation, algorithms laid down in European 
Association of Nuclear Medicine (EANM) guidelines, ICRP 53 approach and a mono-exponential formula (ME), were compared 
with OLINDA/EXM results.
RESULTS: Based on EANM guidelines, activities to be administered were 3% higher in Graves’ disease (p = 0.001) and 3% 
higher in ATN (p = 0.046). Calculated activities using ICRP 53 approach were significantly lower compared to OLINDA/EXM: 33% 
in Graves’ disease; 17% in ATN. Activities recommended by ME, were significantly higher: in Graves’ disease 20%; 42% in ATN. 
CONCLUSIONS: Only EANM algorithm predict quite well, compared to OLINDA/EXM, the required activity to treat hyperthyroid 
patients.
KEY words: Graves’ disease, autonomous thyroid nodule, radioiodine, MIRD, guidelines
Nuclear Med Rev 2015; 18, 1: 13–18
Background
Radioiodine (131I) has been successfully used to treat hyper-
thyroidism ever since Hertz and Roberts used it for the first time on 
humans. This was spring 1941 [1]. Testament to the safety, efficacy 
and convenience of this radiopharmaceutical is the fact that it 
has now become the first-line treatment for hyperthyroidism [2–4]. 
Ever since the start, the activity rate most conducive to optimal 
treatment aroused as a matter of debate: seventy years down the 
line, the clarification of this keeps eluding researchers and physi-
cians alike [5]. Some authors advocate administering a fixed activity 
regimen. In addition to its straightforward applicability, this method 
presents another advantage: namely, in case of treatment failure, 
131I can be redelivered, whereas in case of hypothyroidism, life-long 
treatment with levothyroxine remains a safe option [3, 6]. Other 
authors recommend, instead, using a patient-specific dosimetric 
method based on calculated activities [3]. This is also the approach 
set forth in institutional guidelines, such as the Euratom Directive 
43/97 [7], the ICRU (International Commission on Radiological 
Units and Measurements) Report 67 [8], as well as in the French, 
German and Italian legislations [9–11]. Furthermore, several pa-
pers have reported a dose-related outcome of radioiodine treatment 
[1, 12, 13]. Positive correlation has been identified between hypo-
thyroidism and radiation dose, while the irradiation of non-target 
tissues has also emerged as a factor that needs careful considera-
tion [14]. Several studies have concentrated on autonomous thyroid 
nodules (ATN), highlighting significant post-treatment rates of 
hypothyroidism: still a rather unsatisfactory outcome after seventy 
years of research. Focusing on the dose received by healthy thyroid 
tissues, some authors have found that both lobes — ipsilateral and 
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contralateral — absorbed more than one tenth of the node dose 
[15, 16]. This unnecessary irradiation could perhaps be respon-
sible for the ensuing hypothyroidism. Moreover, roughly 15% of 
hyperthyroid patients have accelerated radioiodine turnover within 
the thyroid gland [17, 18], an outcome attributed to a small thyroid 
iodine pool (small-pool syndrome). This can result in higher than 
expected absorbed doses to the extra-thyroid organs and tissues, 
and particularly to the bone marrow and the blood pool [17, 18]. 
For these reasons, we share with the above-mentioned authors and 
institutions the view that every effort should be made in order to 
keep the irradiation of no-target tissues to the minimum. Once the 
target organ dose has been decided on, a number of methods can 
be applied to estimate the amount of activity required for planned 
dose delivery to the thyroid gland [9, 19]. The Committee on 
Medical Internal Radiation Dose (MIRD) is credited with developing 
a standardised data framework to establish correlations between 
delivered activity and radiation dose [20]. The effectiveness of the 
MIRD approach has been widely discussed and proved excellent 
even compared to more sophisticated methods, such as the Monte 
Carlo calculations [21–23]. OLINDA/EXM is a recent tool, which 
implements the MIRD standard phantom-based methodology de-
veloped for dosimetric purposes [24, 25]. However, institutions such 
as the International Commission on Radiological Protection (ICRP), 
the European Association of Nuclear Medicine and Molecular 
Imaging (EANM), as well as other authors have proposed differ-
ent formulae, based on MIRD formalism, in order to estimate the 
amount of 131I activity needed to reach the planned dose [9, 19, 26]. 
These approaches, which basically simplify biokinetic data, have 
been already used, or advised for use, in nuclear medicine routine 
as well as in research studies [27–29] because they do not require 
any specially engineered device for their application. 
The aim of this study is to evaluate, by using a comparison with 
the results of the OLINDA/EXM software, the European guidelines, 
ICRP approach as well as a simplified formula derived by the MIRD 
formalism, based on a mono-exponential function of radiodiodine 
kinetics (the latter was used by the old Italian guidelines [9]) for esti-
mating the amount of 131I activity to be administered to patients with 
either Graves’ disease or ATN.
Materials and methods
Patient selection
Forty consecutive patients, with either Graves’ disease (n = 28) 
or ATN (n = 12), were included in this explanatory work. All were 
referred to our centre for radioiodine treatment and were suspected 
for fast to very fast iodine metabolism (small-pool syndrome); none 
of the patients was in relapse. Thyrotoxicosis was diagnosed on 
clinical and laboratory findings (high thyroxine, low thyroid-stimu-
lating hormone).
Prior to radioiodine, all patients underwent planar pertechnetate 
scintigraphy and ultrasonography. Following these, either Graves’ 
disease or ATN was diagnosed. With reference to ATN patients, no 
significant uptake was observed in the rest of the gland, i.e. the tracer 
was concentrated within the node. Given their intrinsic ability to show 
the presence of functional tissue, scintigraphic images were also 
used for thyroid mass estimation [30], assuming a density of 1 g/cm3.
Based on the European guidelines [19], all patients were 
instructed to suspend anti-thyroid treatment (methimazole or 
propylthiouracil) at least 10 days before the radioiodine uptake 
test and at least 20 days before radioiodine treatment. The study 
was carried out in accordance with the ethical guidelines of the local 
Ethics Committee for Clinical Investigation. All patients gave their 
informed written consent prior to the Radioiodine Uptake Test (RUT).
Radioiodine uptake test 
Radioiodine uptake test was performed according to standard 
operational procedures for pre-therapeutic dosimetry prior to the 
treatment of benign thyroid diseases [27]. Each patient received 
an orally administered capsule containing 1–3 MBq of [131I] Iodide, 
which was measured at delivery (t = 0). Because these patients, 
based on prior information such as clinical and scintigraphic data, 
were suspected to have a fast iodine metabolism, uptake measure-
ments were performed each hour in the first ten hours and then at 
24, 25, 26, 27, 28, 48, 72 and 96 hours. This approach was studied 
for a correct assessment of iodine uptake in the first phase and of 
iodine dismissing in the second phase. Measurements were per-
formed with a 2-inch NaI(Tl) detector at a 25-centimeter distance 
between detector and source (capsule or thyroid). The energy win-
dow was set at 328–400 keV. All data were corrected for background 
(patient and room, respectively). Three 60-second acquisitions were 
performed for each session and the average was used for suc-
cessive analysis. To ensure optimal reproducibility, all sessions of 
each patient were performed by a single technologist (G.M.D.Y or 
D.B.). Residence time and effective half time were calculated with 
reference to the ratio between each measurement and the measure-
ment at t = 0 of the capsule containing the administered activities, 
as prescribed by official European guidelines [19].
Algorithms and methods used to calculate the activity 
required to deliver a determined radiation dose
In order to estimate the activity necessary to deliver the planned 
dose to thyroid gland or ATN nodule, both OLINDA/EXM and the 
EANM guidelines require knowledge of radioiodine residence time 
within the target tissue. Residence time was calculated based 
on RUT measurements and is equal to the area under the RUT 
measurements-time curve (integral from 0 to infinity of the function 
used to fit the RUT data): 
 [1]
where  is patients’ thyroid uptake at time t, normalized for 
capsule uptake at time 0; U, a and b were estimated with refer-
ence to the function fit and represents radioiodine transfer rate 
(a: elimination from thyroid; b: elimination from blood; U · a: thyroid 
uptake). We chose this function taking into account 131I alleged 
bi-compartmental kinetics (thyroid and blood pool) in benign 
thyroid diseases [10, 11, 27, 31]. In all cases the fit was optimal, 
R2 was higher than 0.90. The residence time (RT) is therefore: 
 [2]
Radioiodine activity to be administered was estimated by the 
mean of OLINDA/EXM given the planned dose and according the 
respective phantom (male/female); subsequently it was corrected 
to match the real size of the gland or nodule.
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To evaluate the radioiodine dose to ATN, we used the OLIN-
DA/EXM Unit Density Sphere Model, in order to better approximate 
the reality, given that the dosimetric calculations becomes highly 
geometry-dependent in small structures [32]. Entering residence 
time data, a list of dose coefficients, expressed in mGy/MBq or 
mGy/mCi, was outputted by OLINDA/EXM. These coefficients are 
reported for different masses of the nodule, in a range of masses be-
tween 0.01 and 6,000 g and in different steps (of 2 g in the range 
2–10 g and in steps of 20 g in the range 20–100 g).
Dose coefficients were fitted very well (R2 > 0.999) according 
to the following power function 
 [3]
k and j values were obtained from the fit in order to obtain dose 
coefficients for the real mass of the patient’s nodule. 
Although based on the MIRD S-value, the EANM guidelines, 
as well as the subsequent standard operational procedures, indi-
cate the following algorithm for activity calculations: 
 [4]
where AEANM [MBq] is the activity to be administered to deliver a tar-
get dose D [Gy], m is the thyroid mass [g], while F is a constant 
derived from S-values and is equal to 
24.7%   [4, 19, 20, 27].
Finally, in order to analyse the required activity independently 
from both the dose and the thyroid mass, the calculated activity nor-
malized by the ratio of the dose to the mass, A/D/m, was considered.
ICRP 53 does not suggest any algorithm for the calculation of the 
activity required to deliver a planned radiation dose to thyroid gland 
or ATN tissues, but proposes a conversion factor for six different 
maximal uptakes of the 20 g thyroid reference mass (5%, 15%, 25%, 
35%, 45%, 55%). A linear function was fitted from these data, and 
the activity was then normalized to the mass of the patient’s thyroid 
as previously reported in a paper which used this protocol to cal-
culate the activity to be administered in hyperthyroid patients [28].
The last algorithm, used in this study even if it is based on 
MIRD formalism, is certainly easier to use given that it does not 
require residence time. This dosimetric protocol has been used in 
various papers [29]; it describes the radioiodine kinetics consider-
ing a Mono-Exponential (ME) function and it was indicated in the 
former Italian guidelines [9]: 
 [5]
where AME [MBq] is the activity to be administered to deliver 
a target dose D [Gy], m is the thyroid mass [g], Umax is the maximal 
uptake value during RUT and T1/2 eff [h] is the effective radioiodine 
half-time during the dismissing phase estimated by logarithmic 
function based on at least three RUT measurements. 
Statistical analysis
In order to compare results obtained by using the various activity 
calculation formulas, we used Student’s paired t test as appro-
priate. All statistically significant levels were set at 5% (p < 0.05). 
SPSS vers. 19 (IBM Corporation, Armonk, NY, USA) was used for 
fitting purposes.
Results 
Thyroid parameters
The mean thyroid/autonomous masses, maximum uptake, target 
doses, effective half-lives and residence times for Graves’ disease and 
ATN, respectively, are illustrated in Table 1. Interestingly, the half-life data 
confirm, although not for all patients, our suspect of patients with fast io-
dine metabolism; their iodine biologic half-life was roughly 10 days [17]. 
Different approaches to determine activities  
to be administered
OLINDA/EXM calculated activities were used as gold stand-
ard. Based on the software calculations, we estimated that for 
patients with Graves’ disease the activities needed to achieve the 
target doses were 644 ± 259 MBq. A/D/m was 0.11 ± 0.08 MBq/ 
/Gy/g. For ATN patients, the required activities were 477 ± 367 MBq, 
while A/D/m was 0.15 ± 0.04 MBq/Gy/g.
Mean activities, as well as A/D/m calculations based on the 
EANM algorithm, on the ICRP 53 approach and ME formula, are 
detailed in Table 2 for Graves’ disease and ATN, while the individual 
values are presented in Figures 1 and 2, respectively.
With reference to the EANM algorithm, the activities to be 
administered and A/D/m were quite similar (+3% in both Graves’ 
disease and ATN). In fact, this applies from a practical point of view 
only, while on statistical point of view the respective values were 
significantly different, due to small, homogeneous differences in 
the algorithm as compared to the reference method. Conversely, 
with reference to the ICRP 53 approach, the activities to be ad-
ministered and A/D/m were much lower both in Graves’ disease 
and in ATN (33% Graves’ disease and 17% in ATN). Finally, with 
reference to the ME dosimetric protocol, the required activities and 
A/D/m were significantly higher both in Graves’ disease and in ATN 
patients (20% in Graves’ disease and 42% in ATN).
Discussion
We worked to fulfil ALARA Principle, international rules and 
national Laws (e.g. in France, in Germany, in Italy). Hyperthyroidism 
Table 1. Data of thyroid or nodule mass, maximum uptake, target dose, effective half time and residence time for Graves’s disease and 
autonomous thyroid nodule
Mass [g] Umax Target Dose (Gy) T1/2eff [h] Res Time [h]
Graves’ (Mean ± SD) 30.7 ± 15.8 0.51 ± 0.13 200 111.1 ± 38.3 96.9 ± 34.3 
ATN (Mean ± SD) 11.3 ± 10.3 0.28 ± 0.05 300 111.7 ± 26.9 58.6 ± 14.1
ATN — autonomous thyroid nodule, SD — standard deviation, Max up — maximal uptake, T1/2 eff (h) — effective half time, Res Time — Residence time, g — gram, Gy — Gray, h — hour
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must be eradicated by employing an individualized activity and the 
lowest dose [8–11]; this was the cornerstone on which was based 
this work. 
Several issues are addressed in this paper: first, the compro-
mise between treatment efficacy and reduction of doses to the 
blood pool/bone marrow (in Graves’ disease patients) or to the 
normal tissues of the thyroid (in ATN patients) is intensely debated 
in the scientific community [14, 16, 33]. This study showed the 
importance of an accurate knowledge of kinetic data in calculation 
of radioiodine activity to be administered in hyperthyroid patients. In 
fact, the estimation of the biodistribution by the mean of residence 
time is more accurate than the assessment with estimated effective 
half-life (such as according to ME) or fixed half-life (such as accord-
ing to ICRP 53). Residence time is, in our view, a key factor, which 
estimation is required by the OLINDA/EXM software. We sampled 
frequently thyroid uptake (18 measurements for each of the 40 
patients), even though we are aware that only continuous measure-
ments could give a precise description of patient-specific iodine 
metabolism. Obviously, this goal cannot be achieved by currently 
available tools, therefore we hope that technology improvements will 
provide more advanced solutions at this regard. At present, such 
a large number of uptake measurements can be performed for 
research purposes only, and cannot become a routine practice in 
nuclear medicine. The effect of reducing the number of measure-
ments without sacrificing accuracy has been successfully tested 
[34], but is beyond the scope of the present study.
Figure 1. The graph shows computed activities, for each patient 
with Graves’ disease, according three methods (triangles for EANM 
Guidelines algorithm, circles for ICRP 53 approach and squares for 
the ME formula). The black line presents the identity-line, i.e. values 
from OLINDA/EXM. Logarithmic scale was used for both axis for visual 
clarity purposes
Figure 2. The graph shows computed activities, for each patient 
with ATN, according three methods (triangles for EANM Guidelines 
algorithm, circles for ICRP 53 approach and squares for the ME 
formula). The black line presents the identity-line, i.e. values from 
OLINDA/EXM. Logarithmic scale was used for both axis for visual 
clarity purposes
Table 2. Activities and activities per unit of Gy and g computed according to each approach (EANM Guidelines algorithm, ICRP 53 approach and 
the ME formula) and their differences with OLINDA/EXM
Approach Pathology Graves’ Disease ATN
Activity (MBq) A/D/m (MBq/Gy/g) Activity (MBq) A/D/m (MBq/Gy/g)
OLINDA/EXM Mean ± SD 644 ± 583 0.11 ± 0.08 477 ± 367 0.15 ± 0.04
ME
 
Mean ± SD 774 ± 667 0.13 ± 0.08 678 ± 606 0.20 ± 0.04
Differences with 
OLINDA/EXM
+20% +20% +42% +31%
p-value < 0.0001 < 0.0001 0.008 < 0.0001
ICRP 53 Mean ± SD 431 ± 230 0.07 ± 0.02 398 ± 321 0.13 ± 0.03
Differences with 
OLINDA/EXM
–33% –31% –17% –15%
p-value 0.017 0.023 0.014 0.012
EANM GL Mean ± SD 662 ± 609 0.11 ± 0.08 493 ± 397 0.15 ± 0.04
Differences with 
OLINDA/EXM
+3% +2% +3% +1%
p-value 0.001 <0.0001 0.046 0.024
GL — guidelines, MBq — Megabecquerel, Gy — Gray, g — gram, SD — standard Deviation, Max up — maximal uptake, T1/2 eff (h) — effective half time
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In the second place, we compared each of three widely 
used protocols [4, 28, 29, 35] as discussed in the previous sec-
tions — the EANM guidelines, ICRP 53 and a ME protocol, indicated 
by the Italian guidelines until 2012 — with OLINDA/EXM. The latter 
was chosen as gold standard because it has been FDA-approved 
for that purpose. As appears from the results of our study, some 
objections can be raised about the ICRP algorithms that do not 
use residence time, and ME dosimetric protocol, which excessively 
simplify patient kinetic. In fact, the ME dosimetric protocol overes-
timates the activities needed by more than 20% (20% in Graves’ 
disease and 42% in ATN). Twenty percent represents the uncertainty 
level observed in our routine activity (unpublished data), and also 
the uncertainty level achievable by well-performed internal MIRD 
dosimetries, as reported in the literature [36]. Since this method 
can lead to higher uncertainties in the single patient even referred 
to the A/D/m parameter (i.e. independently from mass estimation), 
this algorithm showed inadequate at least in patients with fast iodine 
metabolism, for whom the residence time estimated by the method 
does not represent the actual metabolism of these patients.
ICRP 53, on the other hand, relies on a fixed value as effective 
half-time and is only partially patient-dependent. Moreover, since 
the approach has been defined for radioprotection purposes, 
the underlying kinetic data are more representative of a healthy 
population. Although this publication is titled “Radiation Dose to 
Patients from Radiopharmaceuticals”, ICRP 53 proposed data 
that do not describe successfully iodine kinetics in our patients. 
Compared to OLINDA, the ICRP 53 approach appears to under-
estimate required 131I activities, probably because of the difference 
in effective half-time values. Patients with small-pool syndrome 
have a short effective half-time: using a fixed effective half-time 
therefore results in an overestimation of residence time. Finally, it 
should also be considered that the six values for thyroid uptake 
(5%, 15%, 25%, 35%, 45%, 55%) are only a partial representation 
of the wide range of possible uptake data actually measured, and 
almost all values required interpolation (if included in the range 
5–55%) or extrapolation (if higher than 55%). Of the three ap-
proaches considered in this study, the EANM algorithm appears to 
provide the best dose estimation, since it yields very small differ-
ences (3%) compared to OLINDA/EXM. For both methods (EANM 
and OLINDA/EXM), residence time estimation was mandatory 
and the bi-compartmental model was considered adequate for 
a correct determination of residence time [10, 11, 31]. Taking these 
results in due consideration, our routine practice is mostly oriented 
towards the EANM algorithm.
The third issue we addressed, was the use of a Unit-Density 
Sphere Model of OLINDA/EXM in activity estimation for ATN. 
A nodule shape is more similar to a sphere than to a thyroid, 
and the present dosimetric data seems to confirm this. In fact, 
in an ideal sphere the activity needed to deliver the target dose 
is lower than in an ideal ellipsoid; this is particularly important 
for small volumes, since the range of beta particles is compa-
rable with the dimensions of the target object; therefore, the 
dependence of the absorbed dose to the geometry of the target 
increases while the volume reduces [32]. When ATN cases are 
considered, the activities computed with OLINDA are lower when 
using the sphere model compared to the thyroid model (data not 
presented). While the studied protocols apply the same algorithm 
to all benign thyroid diseases, independently from the specific 
pathology, the OLINDA/EXM software allows for a further activity 
personalization. 
Finally, one further remark, the present work is essentially 
a dosimetric analysis. Our aim was to evaluate the best algorithm 
that could be used to calculate the amount of activity needed to 
reach a specific planned dose whenever OLINDA/EXM software 
is not available, whereas estimating the dose-outcome relationship 
was beyond the scope of this paper.
Conclusion
Compared to OLINDA/EXM, ICRP 53 approach and the ME 
dosimetric protocol (without estimation of residence time), although 
easier to be used, failed in accurately estimate activity in Graves’ 
disease and ATN patients because of inadequate characterization 
of iodide metabolism. 
The residence time seems to be well estimated by the 
bi-compartmental model (R2 > 0.90), although this topic was not 
deeply investigated in the present work. In absence of OLINDA/EXM 
software, EANM algorithm seems to allow an accurate calculation 
of the activity required to deliver a determined dose. Finally, The 
sphere model of OLINDA/EXM allows a further personalization on 
the activity calculation in ATN. 
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